BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA
Blinatumomab, a CD19-CD3 bispecific T cell engager (BiTE), has two recombinant single-chain variable fragments that temporarily link CD3+ T cells and CD19+ B cells, leading to the T cell-mediated lysis of neoplastic B cells. Improved minimal residual disease (MRD)-negative response rates and long-t...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2024-08-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://www.mjhid.org/mjhid/article/view/5793 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832543434754228224 |
|---|---|
| author | Ugo Testa Elvira Pelosi Germana Castelli Patrizia Chiusolo |
| author_facet | Ugo Testa Elvira Pelosi Germana Castelli Patrizia Chiusolo |
| author_sort | Ugo Testa |
| collection | DOAJ |
| description |
Blinatumomab, a CD19-CD3 bispecific T cell engager (BiTE), has two recombinant single-chain variable fragments that temporarily link CD3+ T cells and CD19+ B cells, leading to the T cell-mediated lysis of neoplastic B cells. Improved minimal residual disease (MRD)-negative response rates and long-term overall survival have been observed in B-ALL patients who received this drug. These therapeutic successes have led to FDA approval for refractory/relapsed and MRD-positive B-ALL patients. Furthermore, recent studies in newly diagnosed B-ALL patients have led in Philadelphia chromosome-positive patients to the development of chemotherapy-free regimens based on tyrosine kinase inhibitors plus Blinatumomab and in Philadelphia chromosome-negative patients to improvement in outcomes using chemotherapy regimens that have incorporated Blinatumomab in the consolidation phase of treatment.
|
| format | Article |
| id | doaj-art-880f4b38f3164cb48f22c1876c312b46 |
| institution | Kabale University |
| issn | 2035-3006 |
| language | English |
| publishDate | 2024-08-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-880f4b38f3164cb48f22c1876c312b462025-02-03T11:44:24ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062024-08-0116110.4084/MJHID.2024.070BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIAUgo Testa0Elvira Pelosi1Germana Castelli2Patrizia Chiusolo3ISSIstituto Superiore SanitàIstituto Superiore SanitàPoliclinico Gemelli, Universitò Cattolica, Medicina. Blinatumomab, a CD19-CD3 bispecific T cell engager (BiTE), has two recombinant single-chain variable fragments that temporarily link CD3+ T cells and CD19+ B cells, leading to the T cell-mediated lysis of neoplastic B cells. Improved minimal residual disease (MRD)-negative response rates and long-term overall survival have been observed in B-ALL patients who received this drug. These therapeutic successes have led to FDA approval for refractory/relapsed and MRD-positive B-ALL patients. Furthermore, recent studies in newly diagnosed B-ALL patients have led in Philadelphia chromosome-positive patients to the development of chemotherapy-free regimens based on tyrosine kinase inhibitors plus Blinatumomab and in Philadelphia chromosome-negative patients to improvement in outcomes using chemotherapy regimens that have incorporated Blinatumomab in the consolidation phase of treatment. https://www.mjhid.org/mjhid/article/view/5793BlinatumomabALLImmunotherapy; bispecific antibody |
| spellingShingle | Ugo Testa Elvira Pelosi Germana Castelli Patrizia Chiusolo BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA Mediterranean Journal of Hematology and Infectious Diseases Blinatumomab ALL Immunotherapy; bispecific antibody |
| title | BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA |
| title_full | BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA |
| title_fullStr | BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA |
| title_full_unstemmed | BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA |
| title_short | BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA |
| title_sort | blinatumomab in the therapy of acute b lymphoid leukemia |
| topic | Blinatumomab ALL Immunotherapy; bispecific antibody |
| url | https://www.mjhid.org/mjhid/article/view/5793 |
| work_keys_str_mv | AT ugotesta blinatumomabinthetherapyofacuteblymphoidleukemia AT elvirapelosi blinatumomabinthetherapyofacuteblymphoidleukemia AT germanacastelli blinatumomabinthetherapyofacuteblymphoidleukemia AT patriziachiusolo blinatumomabinthetherapyofacuteblymphoidleukemia |